var data={"title":"Taxane-induced pulmonary toxicity","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Taxane-induced pulmonary toxicity</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/contributors\" class=\"contributor contributor_credentials\">Talmadge E King, Jr, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/contributors\" class=\"contributor contributor_credentials\">Kevin R Flaherty, MD, MS</a></dd><dd><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/contributors\" class=\"contributor contributor_credentials\">Reed E Drews, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/contributors\" class=\"contributor contributor_credentials\">Diane MF Savarese, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/contributors\" class=\"contributor contributor_credentials\">Helen Hollingsworth, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jan 09, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The taxanes, <a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">paclitaxel</a> (Taxol), nanoparticle albumin-bound paclitaxel (<a href=\"topic.htm?path=nanoparticle-albumin-bound-paclitaxel-nabpaclitaxel-drug-information\" class=\"drug drug_general\">nabpaclitaxel</a> [Abraxane]), <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a> (Taxotere), and <a href=\"topic.htm?path=cabazitaxel-drug-information\" class=\"drug drug_general\">cabazitaxel</a> (Jevtana), are anti-microtubulin drugs that have a broad range of antitumor activity. These agents have the potential to induce pulmonary injury through a variety of mechanisms:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The most common pulmonary toxicity, interstitial pneumonitis, can develop within days to weeks of receiving <a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">paclitaxel</a> or <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a>, or it may arise later in the course of therapy [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/1\" class=\"abstract_t\">1</a>]. In contrast, interstitial pneumonitis seems to be less common with <a href=\"topic.htm?path=nanoparticle-albumin-bound-paclitaxel-nabpaclitaxel-drug-information\" class=\"drug drug_general\">nabpaclitaxel</a> and with <a href=\"topic.htm?path=cabazitaxel-drug-information\" class=\"drug drug_general\">cabazitaxel</a>, a semisynthetic taxane derivative used for treatment of advanced prostate cancer. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A syndrome of capillary leakage, resulting in peripheral edema, noncardiogenic pulmonary edema, and pleural effusions, has also been reported with <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a> but not with the other taxanes.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Reactions that occur during or shortly after infusion of an antineoplastic agent can be categorized as <span class=\"nowrap\">hypersensitivity/allergic</span> reactions (associated with mast <span class=\"nowrap\">cell/basophil</span> activation) and standard infusion reactions (cytokine mediated) (<a href=\"image.htm?imageKey=PULM%2F76456\" class=\"graphic graphic_table graphicRef76456 \">table 1</a>). The clinical signs and symptoms often include the lungs, and they overlap, although the mechanisms are different. Patients with symptoms and signs to suggest mast <span class=\"nowrap\">cell/basophil</span> mediation (eg, urticaria, angioedema, wheezing, stridor) are at risk for life-threatening anaphylaxis should rechallenge be undertaken (<a href=\"image.htm?imageKey=ALLRG%2F72225\" class=\"graphic graphic_table graphicRef72225 \">table 2</a>). The evaluation of reactions during or shortly after infusion of taxanes is presented in detail elsewhere. (See <a href=\"topic.htm?path=infusion-reactions-to-systemic-chemotherapy\" class=\"medical medical_review\">&quot;Infusion reactions to systemic chemotherapy&quot;</a>.)</p><p/><p>Taxane-induced interstitial pneumonitis and capillary leakage syndrome will be reviewed here. An overview of chemotherapy-induced infusion reactions (which may present with respiratory symptoms) and general issues related to interstitial pneumonitis in adults are presented separately. (See <a href=\"topic.htm?path=infusion-reactions-to-systemic-chemotherapy\" class=\"medical medical_review\">&quot;Infusion reactions to systemic chemotherapy&quot;</a> and <a href=\"topic.htm?path=approach-to-the-adult-with-interstitial-lung-disease-clinical-evaluation\" class=\"medical medical_review\">&quot;Approach to the adult with interstitial lung disease: Clinical evaluation&quot;</a> and <a href=\"topic.htm?path=approach-to-the-adult-with-interstitial-lung-disease-diagnostic-testing\" class=\"medical medical_review\">&quot;Approach to the adult with interstitial lung disease: Diagnostic testing&quot;</a> and <a href=\"topic.htm?path=acute-interstitial-pneumonia-hamman-rich-syndrome\" class=\"medical medical_review\">&quot;Acute interstitial pneumonia (Hamman-Rich syndrome)&quot;</a> and <a href=\"topic.htm?path=idiopathic-interstitial-pneumonias-clinical-manifestations-and-pathology\" class=\"medical medical_review\">&quot;Idiopathic interstitial pneumonias: Clinical manifestations and pathology&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">INTERSTITIAL PNEUMONITIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The interstitial pneumonitis induced by the taxanes, <a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">paclitaxel</a>, nanoparticle albumin-bound paclitaxel (<a href=\"topic.htm?path=nanoparticle-albumin-bound-paclitaxel-nabpaclitaxel-drug-information\" class=\"drug drug_general\">nabpaclitaxel</a>), <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a>, and <a href=\"topic.htm?path=cabazitaxel-drug-information\" class=\"drug drug_general\">cabazitaxel</a>, is thought to represent an immune-mediated delayed hypersensitivity reaction [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/1,2\" class=\"abstract_t\">1,2</a>]. In one case report, the patient underwent bronchoalveolar lavage (BAL), and the BAL lymphocytes showed a positive leukocyte migration inhibition test to paclitaxel [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/3\" class=\"abstract_t\">3</a>]. Based on this finding, paclitaxel (rather than its vehicle Cremophor) was judged responsible, via a cell-mediated (type IV) delayed reaction (<a href=\"image.htm?imageKey=PULM%2F71375\" class=\"graphic graphic_table graphicRef71375 \">table 3</a>).</p><p>Although most cases follow intravenous use of the taxane, fatal acute interstitial pneumonitis has also been described in patients after insertion of paclitaxel-eluting intracoronary stents. (See <a href=\"topic.htm?path=drug-eluting-intracoronary-stents-general-principles#H21\" class=\"medical medical_review\">&quot;Drug-eluting intracoronary stents: General principles&quot;, section on 'Hypersensitivity reactions'</a>.)</p><p>Interstitial lung disease may rarely occur with more chronic dosing, and progression to pulmonary fibrosis has been described [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/4\" class=\"abstract_t\">4</a>]. Whether the mechanism underlying chronic interstitial pneumonitis is similar to that responsible for the <span class=\"nowrap\">acute/subacute</span> presentation is unclear.</p><p class=\"headingAnchor\" id=\"H1346056356\"><span class=\"h2\">Paclitaxel, docetaxel, and nabpaclitaxel</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are multiple reports of acute or subacute, diffuse interstitial lung disease developing within hours or a few weeks after <a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">paclitaxel</a> [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/1,5-9\" class=\"abstract_t\">1,5-9</a>] or <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a> administration [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/2,10-12\" class=\"abstract_t\">2,10-12</a>]; there are fewer reports detailing pneumonitis after administration of <a href=\"topic.htm?path=nanoparticle-albumin-bound-paclitaxel-nabpaclitaxel-drug-information\" class=\"drug drug_general\">nabpaclitaxel</a>, and most of these events appear to be mild, meaning that they are probably underreported in published clinical trials [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/13\" class=\"abstract_t\">13</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h3\">Incidence and impact of dose and schedule</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Approximately 1 to 5 percent of patients receiving conventional-dose <a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">paclitaxel</a> or <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a> on an every-three-week schedule develop pneumonitis of grade 3 or higher (<a href=\"image.htm?imageKey=ONC%2F61493\" class=\"graphic graphic_table graphicRef61493 \">table 4</a>) severity during therapy [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/4,12,14-20\" class=\"abstract_t\">4,12,14-20</a>].</p><p>There is a modest dose effect within the range of <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a> doses that are used in the clinic. This was shown in a phase III trial conducted in women with advanced breast cancer, in which there was a slightly but significantly higher incidence of grade 3 or 4 (<a href=\"image.htm?imageKey=ONC%2F61493\" class=\"graphic graphic_table graphicRef61493 \">table 4</a>) pulmonary toxicity with docetaxel doses of 100 <span class=\"nowrap\">mg/m<sup>2</sup></span> as compared with 60 <span class=\"nowrap\">mg/m<sup>2</sup></span> (2.2 versus 0.7 percent) [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/21\" class=\"abstract_t\">21</a>]. A case of lethal pneumonitis was reported eight days after a patient received a fourth dose of docetaxel at 100 <span class=\"nowrap\">mg/m<sup>2</sup>;</span> autopsy disclosed severe interstitial fibrosis that was attributed to docetaxel [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/22\" class=\"abstract_t\">22</a>].</p><p>No differences in rates of pneumonitis have been reported in trials comparing <a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">paclitaxel</a> doses within a range that does not require growth factor or hematopoietic stem cell support (eg, 175 versus 225 or 250 <span class=\"nowrap\">mg/m<sup>2</sup></span> of paclitaxel [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/23,24\" class=\"abstract_t\">23,24</a>]). However, interstitial pneumonitis has been seen more commonly with higher paclitaxel doses that require growth factor or hematopoietic stem cell support [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/25,26\" class=\"abstract_t\">25,26</a>]. In fact, acute pneumonitis has been dose limiting in phase I trials of paclitaxel [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/26\" class=\"abstract_t\">26</a>].</p><p>There is some evidence to suggest that weekly as compared with every-three-week dosing of <a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">paclitaxel</a> increases the incidence or severity of pneumonitis, although the data are conflicting:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a phase III trial directly comparing weekly with every-three-week <a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">paclitaxel</a> administration in women with advanced breast cancer, rates of grade 3 or higher (<a href=\"image.htm?imageKey=ONC%2F61493\" class=\"graphic graphic_table graphicRef61493 \">table 4</a>) dyspnea during therapy were 7 and 4 percent, respectively, with weekly or every-three-week treatment. There were two deaths due to pneumonia on the weekly schedule [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/19\" class=\"abstract_t\">19</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Another comparative trial suggests a higher rate of pneumonitis in patients receiving weekly as compared with every-three-week <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a> [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/20\" class=\"abstract_t\">20</a>]. Of the 60 patients receiving weekly therapy, interstitial pneumonia developed in 16 (27 percent), and it was grade 1 or 2 (<a href=\"image.htm?imageKey=ONC%2F61493\" class=\"graphic graphic_table graphicRef61493 \">table 4</a>) in 13 and grade 3 or 4 in three (5 percent). By comparison, interstitial pneumonia only developed in 2 of the 33 patients receiving standard every-three-week therapy (6 percent), only one of which was grade 3.</p><p/><p>On the other hand, as noted above, rates of pneumonitis with weekly administration of <a href=\"topic.htm?path=nanoparticle-albumin-bound-paclitaxel-nabpaclitaxel-drug-information\" class=\"drug drug_general\">nabpaclitaxel</a> seem to be lower. A phase III trial compared weekly administration of nabpaclitaxel (100 <span class=\"nowrap\">mg/m<sup>2</sup>)</span> plus <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">carboplatin</a> every three weeks with non-bound <a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">paclitaxel</a> (200 <span class=\"nowrap\">mg/m<sup>2</sup>)</span> and carboplatin, each given every three weeks in over 1000 patients with non-small cell lung cancer (NSCLC), and reported no significant grade 3 or greater pulmonary toxicity in either arm [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/27\" class=\"abstract_t\">27</a>].</p><p>Patients with preexisting lung disease appear to have an increased risk of pneumonitis with <a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">paclitaxel</a> and <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a>. In a retrospective series of 392 Japanese patients with NSCLC who were treated with docetaxel (60 <span class=\"nowrap\">mg/m<sup>2</sup>)</span> every three weeks, the incidence of interstitial lung disease was 4.6 percent, but it was 26 percent in patients with preexisting interstitial lung disease [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/12\" class=\"abstract_t\">12</a>]. Two other reports in which patients with underlying interstitial lung disease were treated with docetaxel noted acute exacerbation of the interstitial lung disease in 14 and 18 percent, respectively, with one-half of the reactions resulting in death [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/28,29\" class=\"abstract_t\">28,29</a>]. </p><p>In our view, preexisting interstitial lung disease should be considered a relative contraindication to taxane treatment. However, at least one case report describes successful treatment with <a href=\"topic.htm?path=nanoparticle-albumin-bound-paclitaxel-nabpaclitaxel-drug-information\" class=\"drug drug_general\">nabpaclitaxel</a> in a patient with NSCLC and a history of interstitial lung disease [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/30\" class=\"abstract_t\">30</a>]. </p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h3\">Concomitant drugs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The incidence of taxane-induced pneumonitis seems to be higher when taxanes are combined with other cytotoxic agents [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/1,9,15,31-38\" class=\"abstract_t\">1,9,15,31-38</a>]. In particular, the combination of taxanes plus <a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">gemcitabine</a> appears to result in significantly more pulmonary toxicity than seen with a taxane alone [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/9,15,16,31-36,38,39\" class=\"abstract_t\">9,15,16,31-36,38,39</a>]:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In one series, 4 of 12 patients (33 percent) with NSCLC who were treated with the combination of <a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">paclitaxel</a> and <a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">gemcitabine</a> developed grade 2 or worse (<a href=\"image.htm?imageKey=ONC%2F61493\" class=\"graphic graphic_table graphicRef61493 \">table 4</a>) pneumonitis [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/9\" class=\"abstract_t\">9</a>]. The diagnosis was made on the basis of high-resolution computed tomography (CT) scanning, and all patients responded to high-dose glucocorticoids within a week or less. No patient had received thoracic radiotherapy (RT) at any time during the course of the illness.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In two other reports, grade 3 or worse interstitial lung disease was observed in 4 of 39 (10 percent) and 7 of 63 (11 percent) patients treated with the combination of <a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">paclitaxel</a> plus <a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">gemcitabine</a> or <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a> plus gemcitabine, respectively [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/32,40\" class=\"abstract_t\">32,40</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a meta-analysis, the incidence of severe (grade 3 or worse) lung toxicity with combined <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a> plus <a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">gemcitabine</a> was 2.7 percent (95% CI 2.26-3.14); the proportion of fatal cases was 0.35 percent [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/39\" class=\"abstract_t\">39</a>]. Patients treated for lung cancer were at a higher risk for severe pulmonary toxicity than were those treated for breast cancer (4 versus 0.8 percent).</p><p/><p class=\"headingAnchor\" id=\"H7\"><span class=\"h3\">Concomitant radiotherapy</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Taxanes are often used in conjunction with RT and are considered radiosensitizers. Thoracic RT is associated with lung damage, but concomitant therapy with <a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">paclitaxel</a>, <a href=\"topic.htm?path=nanoparticle-albumin-bound-paclitaxel-nabpaclitaxel-drug-information\" class=\"drug drug_general\">nabpaclitaxel</a>, or <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a> and lung irradiation can cause pulmonary disease beyond that attributable to RT alone [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/41-44\" class=\"abstract_t\">41-44</a>]. (See <a href=\"topic.htm?path=radiation-induced-lung-injury\" class=\"medical medical_review\">&quot;Radiation-induced lung injury&quot;</a>.)</p><p>As examples:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a trial of concurrent <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a>, weekly <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a>, and thoracic RT for NSCLC, pneumonitis of grade 3 or greater severity (<a href=\"image.htm?imageKey=ONC%2F61493\" class=\"graphic graphic_table graphicRef61493 \">table 4</a>) was observed in 4 of 34 (12 percent) patients, while 44 percent had grade 1 or 2 pneumonitis [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/41\" class=\"abstract_t\">41</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A trial of concurrent RT and weekly <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a> in stage III NSCLC reported a 47 percent rate of grade 3 or worse pneumonitis; the high rate was thought to be related to a large volume of irradiated lung [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/42\" class=\"abstract_t\">42</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>A phase II study of <a href=\"topic.htm?path=nanoparticle-albumin-bound-paclitaxel-nabpaclitaxel-drug-information\" class=\"drug drug_general\">nabpaclitaxel</a> plus <a href=\"topic.htm?path=carboplatin-drug-information\" class=\"drug drug_general\">carboplatin</a> in combination with thoracic radiation reported grade 2 or more severe radiation pneumonitis in all three patients who had more than 30 percent of the lung volume treated to at least 20 Gy [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/44\" class=\"abstract_t\">44</a>].</p><p/><p>The use of sequential rather than concurrent administration of taxanes and chest wall RT appears to reduce, although not eliminate, the excess risk of pneumonitis [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/37,45-50\" class=\"abstract_t\">37,45-50</a>]. As an example, a North American trial reported grade 3 to 5 (<a href=\"image.htm?imageKey=ONC%2F61493\" class=\"graphic graphic_table graphicRef61493 \">table 4</a>) pneumonitis in 10 percent of 73 patients (one death) treated with <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a> consolidation chemotherapy after <a href=\"topic.htm?path=cisplatin-drug-information\" class=\"drug drug_general\">cisplatin</a> and <a href=\"topic.htm?path=etoposide-drug-information\" class=\"drug drug_general\">etoposide</a> plus concurrent chest irradiation [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/46\" class=\"abstract_t\">46</a>]. In a separate study, a shorter interval between RT and taxane initiation was associated with a greater risk of pneumonitis [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/51\" class=\"abstract_t\">51</a>].</p><p class=\"headingAnchor\" id=\"H2722231576\"><span class=\"h3\">Patterns of disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Symptom onset varies from a few days after the first dose to weeks following completion of chemotherapy. </p><p><a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">Paclitaxel</a> has been associated with acute diffuse interstitial pneumonia (which may progress to acute respiratory failure), subacute diffuse interstitial pneumonitis (with a pattern similar to, but often less severe than, the acute form), pulmonary opacities with peripheral eosinophilia, and pulmonary fibrosis [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/1,4,52,53\" class=\"abstract_t\">1,4,52,53</a>]. Patients may have respiratory symptoms starting after the first treatment that worsen with subsequent exposures, or may develop symptoms weeks after completion of several cycles [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/4\" class=\"abstract_t\">4</a>].</p><p>Rare cases of fatal acute interstitial pneumonitis (diffuse alveolar damage) have been described three to seven days after implantation of a paclitaxel-eluting stent [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/54\" class=\"abstract_t\">54</a>]. (See <a href=\"topic.htm?path=drug-eluting-intracoronary-stents-general-principles#H21\" class=\"medical medical_review\">&quot;Drug-eluting intracoronary stents: General principles&quot;, section on 'Hypersensitivity reactions'</a>.)</p><p><a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">Docetaxel</a> has been associated with acute or subacute diffuse interstitial pneumonia, usually developing after the second cycle, but occasionally as early as the first cycle or as late as the ninth cycle [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/12\" class=\"abstract_t\">12</a>]. This is different from the capillary leakage phenomenon associated with the early onset peripheral edema, noncardiogenic pulmonary edema, and pleural effusions described below. (See <a href=\"#H11\" class=\"local\">'Capillary leakage and docetaxel'</a> below.)</p><p class=\"headingAnchor\" id=\"H3973614121\"><span class=\"h3\">Clinical manifestations</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical manifestations of taxane-induced pneumonitis are nonspecific and include the following:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Symptoms and physical examination</strong> <strong>findings</strong> &ndash; Symptoms of taxane-induced interstitial pneumonitis include dyspnea (at rest or with exertion), dry cough, malaise, and low-grade fever [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/1,11\" class=\"abstract_t\">1,11</a>]. Tachypnea, hypoxemia, and crackles may be present.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Imaging</strong> &ndash; The radiographic features of taxane-induced pneumonitis are nonspecific and similar to other cases of drug-induced pneumonitis [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/1,11,12\" class=\"abstract_t\">1,11,12</a>]. Chest radiographs and high-resolution CT scans typically show an increase in reticular markings in a patchy or diffuse pattern with or without ground glass opacities (<a href=\"image.htm?imageKey=PULM%2F51035\" class=\"graphic graphic_diagnosticimage graphicRef51035 \">image 1</a>) [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/55-57\" class=\"abstract_t\">55-57</a>]. A peribronchial distribution of ground glass opacities has been reported [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/58\" class=\"abstract_t\">58</a>]. Focal opacities or dense <span class=\"nowrap\">nodules/consolidation</span> with or without air bronchograms may be seen in patients with pulmonary parenchymal infiltration with eosinophils or organizing pneumonia-type reactions [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/59\" class=\"abstract_t\">59</a>]. (See <a href=\"topic.htm?path=high-resolution-computed-tomography-of-the-lungs#H4\" class=\"medical medical_review\">&quot;High resolution computed tomography of the lungs&quot;, section on 'HRCT patterns'</a>.)</p><p/><p class=\"headingAnchor\" id=\"H1549027504\"><span class=\"h3\">Diagnostic evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of taxane-induced pneumonitis is usually based on the combination of a compatible clinical pattern, exposure history, and the exclusion of other causes of diffuse pulmonary opacities, such as infection, radiation pneumonitis, alveolar hemorrhage, reaction to a separate antineoplastic agent, pulmonary involvement by the underlying malignancy, heart failure, and noncardiogenic pulmonary edema (for those on <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a>). (See <a href=\"#H11\" class=\"local\">'Capillary leakage and docetaxel'</a> below.)</p><p>The evaluation will often include laboratory testing, BAL (particularly when systemic glucocorticoid therapy is contemplated), and rarely, lung biopsy. As with other antineoplastic agents, improvement in the interstitial pneumonitis following cessation of taxane therapy supports the diagnosis. The evaluation and diagnosis of interstitial lung disease associated with antineoplastic therapy are discussed separately. (See <a href=\"topic.htm?path=pulmonary-toxicity-associated-with-systemic-antineoplastic-therapy-clinical-presentation-diagnosis-and-treatment#H11\" class=\"medical medical_review\">&quot;Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment&quot;, section on 'Diagnosis'</a> and <a href=\"topic.htm?path=pulmonary-toxicity-associated-with-systemic-antineoplastic-therapy-clinical-presentation-diagnosis-and-treatment#H15\" class=\"medical medical_review\">&quot;Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment&quot;, section on 'Differential diagnosis'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Laboratory testing</strong> &ndash; Laboratory testing is used to determine whether other disease processes are contributory and often includes complete cell counts, coagulation tests, B-type natriuretic peptide (BNP), blood cultures, sputum cultures, and viral and fungal serology and DNA analysis.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Bronchoalveolar lavage</strong> &ndash; The main purpose of BAL is to exclude other processes, such as infection, alveolar hemorrhage, or metastatic spread of the underlying cancer. Patients with acute taxane-induced pneumonitis often have lymphocytosis in the BAL specimen; increased eosinophils has also been noted [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/52,53\" class=\"abstract_t\">52,53</a>]. (See <a href=\"topic.htm?path=role-of-bronchoalveolar-lavage-in-diagnosis-of-interstitial-lung-disease\" class=\"medical medical_review\">&quot;Role of bronchoalveolar lavage in diagnosis of interstitial lung disease&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Surgical lung biopsy</strong> &ndash; Lung biopsy is rarely indicated and usually reserved for patients with progressive lung disease despite cessation of taxane therapy when the cause of the pneumonitis is uncertain. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Histopathology</strong> &ndash; Histopathologic findings in taxane-induced pneumonitis include nonspecific interstitial pneumonia, organizing pneumonia, eosinophilic infiltration, and diffuse alveolar damage with intraalveolar and interstitial foamy macrophages [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/1,3,11,53,60,61\" class=\"abstract_t\">1,3,11,53,60,61</a>]. (See <a href=\"topic.htm?path=role-of-lung-biopsy-in-the-diagnosis-of-interstitial-lung-disease\" class=\"medical medical_review\">&quot;Role of lung biopsy in the diagnosis of interstitial lung disease&quot;</a>.)</p><p/><p>The differential diagnosis of taxane-induced lung toxicity is similar to that of lung toxicity due to other antineoplastic agents and includes infection and lung involvement by the primary malignancy. (See <a href=\"topic.htm?path=pulmonary-toxicity-associated-with-systemic-antineoplastic-therapy-clinical-presentation-diagnosis-and-treatment#H15\" class=\"medical medical_review\">&quot;Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment&quot;, section on 'Differential diagnosis'</a>.)</p><p>For patients on <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a>, acute pneumonitis needs to be differentiated from acute permeability edema, which is thought to reflect a capillary leakage phenomenon and is associated with peripheral edema. (See <a href=\"#H11\" class=\"local\">'Capillary leakage and docetaxel'</a> below.) </p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h3\">Treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Treatment of taxane-induced pneumonitis is empiric and primarily consists of cessation of taxane therapy. The decision to initiate glucocorticoid therapy usually depends on the severity and rapidity of worsening of pulmonary impairment. </p><p>Glucocorticoids are generally reserved for patients with more severe pulmonary toxicity (eg, dyspnea at rest, a decrease in oxygen saturation below 90 percent or a more than 4 percent decrease from baseline, or worsening clinical status). When considering systemic glucocorticoid therapy, it is mandatory to exclude an infectious etiology with appropriate laboratory testing and cultures, often including bronchoscopy and BAL. Empiric antimicrobial therapy directed at likely pathogens is often indicated while diagnostic procedures and cultures are performed.</p><p>There is no established glucocorticoid treatment schedule, but severe respiratory compromise is often treated with <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> 40 to 60 mg daily; intravenous glucocorticoids may be used in patients who have impending respiratory failure [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/58\" class=\"abstract_t\">58</a>]. If the patient's response permits, tapering of the dose can be carried out over one to two months.</p><p>The rationale for using systemic glucocorticoid therapy in selected patients is based upon case reports suggesting an immunologic mechanism (eg, biopsy evidence of hypersensitivity pneumonitis), and anecdotal observation of benefit, particularly in cases that have an acute or subacute presentation [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/1,11,58,62\" class=\"abstract_t\">1,11,58,62</a>]. </p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients with an acute or subacute onset of pneumonitis due to <a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">paclitaxel</a> or <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a>, drug cessation and treatment with systemic glucocorticoids usually rapidly reverse the pneumonitis and improve oxygenation [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/1,6,11\" class=\"abstract_t\">1,6,11</a>]. Three patients with diffuse pneumonitis and hypoxemia (pulse oxygen saturation &lt;90 percent) associated with paclitaxel therapy had complete resolution of symptoms and radiographic opacities with high-dose <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/1\" class=\"abstract_t\">1</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a report of two patients with respiratory failure due to taxanes (one after four courses of <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a> and one after a single course of <a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">paclitaxel</a>), both patients experienced resolution of pneumonitis with glucocorticoid treatment [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/62\" class=\"abstract_t\">62</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In a literature review of 31 cases of interstitial pneumonitis associated with <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a> (either alone or in combination with other drugs, including <a href=\"topic.htm?path=cyclophosphamide-drug-information\" class=\"drug drug_general\">cyclophosphamide</a> and <a href=\"topic.htm?path=gemcitabine-drug-information\" class=\"drug drug_general\">gemcitabine</a>), pneumonitis improved or resolved with glucocorticoids in 18 and resulted in death in 12 (despite glucocorticoids in 11); outcome was unknown in one [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/11\" class=\"abstract_t\">11</a>]. </p><p/><p>Patients who develop taxane-associated acute interstitial pneumonitis with biopsy evidence of diffuse alveolar damage may progress to life-threatening respiratory failure despite glucocorticoid therapy [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/2,10,11,63\" class=\"abstract_t\">2,10,11,63</a>]. Other patients with subacute pneumonitis have developed progressive respiratory failure and death despite drug discontinuation and systemic glucocorticoids [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/10,64\" class=\"abstract_t\">10,64</a>]. (See <a href=\"topic.htm?path=acute-interstitial-pneumonia-hamman-rich-syndrome\" class=\"medical medical_review\">&quot;Acute interstitial pneumonia (Hamman-Rich syndrome)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H4158011296\"><span class=\"h2\">Cabazitaxel</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Interstitial pneumonitis, interstitial lung disease, and acute respiratory distress syndrome have been reported in patients treated with <a href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/201023s017lbl.pdf&amp;token=0WZXu4Pzvrv+EjlG+sV1bgjy01XzWW08Ts4tizhLI/lgeyafpgkUicQJJDBwSh39gudklQ+5mKecLsI21d0gFhx4BhUUsO7faxO/WZ1zeCk=&amp;TOPIC_ID=4355\" target=\"_blank\" class=\"external\">cabazitaxel</a>, although the frequency is not known. Patients with underlying lung disease may be at higher risk. The optimal form of treatment is not established. However, the <a href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/201023s017lbl.pdf&amp;token=0WZXu4Pzvrv+EjlG+sV1bgjy01XzWW08Ts4tizhLI/lgeyafpgkUicQJJDBwSh39gudklQ+5mKecLsI21d0gFhx4BhUUsO7faxO/WZ1zeCk=&amp;TOPIC_ID=4355\" target=\"_blank\" class=\"external\">US Prescribing Information</a> suggests interrupting therapy for any new or worsening pulmonary symptoms. Corticosteroids may be indicated with severe exacerbations since they have been shown to be of benefit with pulmonary toxicity induced by other taxanes.</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h1\">CAPILLARY LEAKAGE AND DOCETAXEL</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Some patients receiving <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a> develop serious problems with fluid retention, attributed to capillary leakage. This side effect appears to be most closely related to the total dose of docetaxel administered, but the incidence and severity can be reduced by glucocorticoid pretreatment [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/65-67\" class=\"abstract_t\">65-67</a>].</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Clinical manifestations</strong> &ndash; Clinically, capillary leakage is usually manifest as peripheral edema and weight gain, although pulmonary vascular leak can also occur, leading to noncardiogenic pulmonary edema <span class=\"nowrap\">and/or</span> pleural effusions [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/36,68\" class=\"abstract_t\">36,68</a>]. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Diagnosis </strong>&ndash;<strong> </strong>For patients who develop capillary leakage, the first sign of fluid retention is body weight gain. The diagnosis of noncardiogenic pulmonary edema or pleural effusion is suggested by the time course, concomitant peripheral edema, dyspnea, pulmonary opacities, or pleural effusion on imaging studies, and lack of fever.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Treatment</strong> &ndash; Treatment with diuretics at the first sign of weight gain appears to be effective in limiting the severity of docetaxel-induced fluid retention. If the <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a> is continued and the fluid retention not treated, it may progress to pleural <span class=\"nowrap\">and/or</span> pericardial effusions, pulmonary edema, and ascites. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Prevention</strong> &ndash; The optimal premedication schedule has not been determined, but a common practice is to administer <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> premedication (8 mg orally, every 12 hours for six doses, beginning 24 hours prior to <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a> injection), typically given to prevent docetaxel-related fluid retention [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/69-71\" class=\"abstract_t\">69-71</a>]. This dose is also used to prevent hypersensitivity reactions to docetaxel. Lower dexamethasone doses may be used in patients receiving weekly docetaxel [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/72\" class=\"abstract_t\">72</a>]. With premedication, approximately 50 percent of patients experience peripheral edema that can be controlled with diuretics, and the median cumulative dose to onset of moderate to severe fluid retention is approximately 480 <span class=\"nowrap\">mg/m<sup>2</sup></span> (range 60 to 780) [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/73\" class=\"abstract_t\">73</a>]. (See <a href=\"topic.htm?path=infusion-reactions-to-systemic-chemotherapy#H32\" class=\"medical medical_review\">&quot;Infusion reactions to systemic chemotherapy&quot;, section on 'Taxanes'</a>.) </p><p/><p class=\"headingAnchor\" id=\"H12\"><span class=\"h1\">RADIATION RECALL</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Rare reports describe radiation recall pneumonitis with <a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">paclitaxel</a> and <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a>. Radiation recall is characterized by the onset of cough and dyspnea associated with radiographic lung opacities that conform to the prior radiation field. (See <a href=\"topic.htm?path=radiation-induced-lung-injury#H108098608\" class=\"medical medical_review\">&quot;Radiation-induced lung injury&quot;, section on 'Radiation recall'</a>.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">Paclitaxel</a> was associated with recall pneumonitis in a patient who had previously received radiotherapy for a non-small cell lung cancer [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/74\" class=\"abstract_t\">74</a>]. A single dose of <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a> 20 mg was associated with symptomatic improvement. Premedication was administered with dexamethasone 20 mg orally 24 hours, 12 hours, and immediately before the next dose of paclitaxel, without a recurrence of cough or dyspnea. </p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Radiation recall pneumonitis was considered possible in 2 of 19 patients receiving <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a> and <a href=\"topic.htm?path=bexarotene-drug-information\" class=\"drug drug_general\">bexarotene</a> chemotherapy [<a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/75\" class=\"abstract_t\">75</a>]. </p><p/><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"headingAnchor\" id=\"H3200253800\"><span class=\"h2\">Interstitial pneumonitis</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diffuse interstitial pneumonitis may present within days (acute) to weeks (subacute) of starting <a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">paclitaxel</a>, nanoparticle albumin-bound paclitaxel (<a href=\"topic.htm?path=nanoparticle-albumin-bound-paclitaxel-nabpaclitaxel-drug-information\" class=\"drug drug_general\">nabpaclitaxel</a>), <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a>, or <a href=\"topic.htm?path=cabazitaxel-drug-information\" class=\"drug drug_general\">cabazitaxel</a>, or later in the course of therapy. (See <a href=\"#H4\" class=\"local\">'Interstitial pneumonitis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The incidence and severity depend on dose, schedule, concurrent chemotherapy agents, and use of concurrent or sequential radiotherapy. The incidence may be lower with <a href=\"topic.htm?path=nanoparticle-albumin-bound-paclitaxel-nabpaclitaxel-drug-information\" class=\"drug drug_general\">nabpaclitaxel</a> than with <a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">paclitaxel</a>. Patients with underlying interstitial lung disease have an increased incidence of pneumonitis related to paclitaxel and <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a>. (See <a href=\"#H1346056356\" class=\"local\">'Paclitaxel, docetaxel, and nabpaclitaxel'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We avoid <a href=\"topic.htm?path=paclitaxel-conventional-drug-information\" class=\"drug drug_general\">paclitaxel</a> and <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a>, if at all possible, in patients with underlying interstitial lung disease, due to the increased incidence of taxane-induced pneumonitis. (See <a href=\"#H4\" class=\"local\">'Interstitial pneumonitis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Clinical features of taxane-induced pneumonitis are nonspecific and include exertional dyspnea, dry cough, malaise, and low-grade fever. Tachypnea, hypoxemia, and crackles may be present on examination. Imaging findings are also nonspecific. (See <a href=\"#H3973614121\" class=\"local\">'Clinical manifestations'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of taxane-induced pneumonitis is based upon the combination of a compatible clinical pattern, exposure history, and the exclusion of other causes of diffuse pulmonary opacities. Bronchoalveolar lavage (BAL) is frequently used to exclude infection, hemorrhage, and malignancy. A lung biopsy is rarely needed. (See <a href=\"#H1549027504\" class=\"local\">'Diagnostic evaluation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Treatment of taxane-induced interstitial pneumonitis is empiric and primarily consists of permanent discontinuation of the taxane. General supportive care (eg, supplemental oxygen) is administered as necessary. The decision to initiate glucocorticoid therapy depends on the severity and rapidity of worsening of pulmonary impairment. When considering the option of systemic glucocorticoid therapy, it is mandatory to exclude an infectious etiology with appropriate stains and cultures, often including bronchoscopy and BAL. Empiric antimicrobial therapy directed at likely pathogens is often indicated while diagnostic procedures and cultures are performed. (See <a href=\"#H10\" class=\"local\">'Treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients with severe symptomatic pneumonitis (eg, dyspnea at rest, a decrease in oxygen saturation below 90 percent or a more than 4 percent decrease from baseline, or worsening clinical status), we suggest initiating systemic glucocorticoid therapy rather than observation alone (<a href=\"grade.htm?i=5\" class=\"grade\">Grade 2B</a>). We generally use oral <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> 40 to 60 mg daily; intravenous glucocorticoids may be used initially in patients who have impending respiratory failure. If the clinical response permits, tapering of the dose can be carried out over one to two months. (See <a href=\"#H10\" class=\"local\">'Treatment'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Many cases of taxane-induced pneumonitis will resolve with drug discontinuation and observation, or treatment with glucocorticoids, although fatalities have been reported. (See <a href=\"#H10\" class=\"local\">'Treatment'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H18\"><span class=\"h2\">Docetaxel-related capillary leakage</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">Docetaxel</a> is associated with fluid retention that is dose-related and attributed to a capillary leakage phenomenon. The usual initial symptoms are peripheral edema and weight gain, which can progress to noncardiogenic pulmonary edema <span class=\"nowrap\">and/or</span> pleural effusions if untreated. (See <a href=\"#H11\" class=\"local\">'Capillary leakage and docetaxel'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For patients who develop peripheral edema while receiving <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a>, we suggest early treatment with daily diuretics to limit the severity of fluid retention (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H11\" class=\"local\">'Capillary leakage and docetaxel'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend glucocorticoid premedication prior to <a href=\"topic.htm?path=docetaxel-drug-information\" class=\"drug drug_general\">docetaxel</a> administration to reduce the incidence and severity of fluid retention (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). The usual glucocorticoid is <a href=\"topic.htm?path=dexamethasone-drug-information\" class=\"drug drug_general\">dexamethasone</a>, given 8 mg orally, every 12 hours for six doses, beginning 24 hours prior to docetaxel infusion; lower dexamethasone doses may be used in patients receiving weekly docetaxel. (See <a href=\"#H11\" class=\"local\">'Capillary leakage and docetaxel'</a> above.)</p><p/><p class=\"headingAnchor\" id=\"H1393696056\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge James Jett, MD, who contributed to an earlier version of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/1\" class=\"nounderline abstract_t\">Bielopolski D, Evron E, Moreh-Rahav O, et al. Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature. J Chemother 2017; 29:113.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/2\" class=\"nounderline abstract_t\">Wang GS, Yang KY, Perng RP. Life-threatening hypersensitivity pneumonitis induced by docetaxel (taxotere). Br J Cancer 2001; 85:1247.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/3\" class=\"nounderline abstract_t\">Fujimori K, Yokoyama A, Kurita Y, et al. Paclitaxel-induced cell-mediated hypersensitivity pneumonitis. Diagnosis using leukocyte migration test, bronchoalveolar lavage and transbronchial lung biopsy. Oncology 1998; 55:340.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/4\" class=\"nounderline abstract_t\">Ostoros G, Pretz A, Fillinger J, et al. Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature. Int J Gynecol Cancer 2006; 16 Suppl 1:391.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/5\" class=\"nounderline abstract_t\">Ramanathan RK, Belani CP. Transient pulmonary infiltrates: a hypersensitivity reaction to paclitaxel. Ann Intern Med 1996; 124:278.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/6\" class=\"nounderline abstract_t\">Khan A, McNally D, Tutschka PJ, Bilgrami S. Paclitaxel-induced acute bilateral pneumonitis. Ann Pharmacother 1997; 31:1471.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/7\" class=\"nounderline abstract_t\">Yasuda K, Igishi T, Kawasaki Y, et al. Phase II trial of weekly paclitaxel in previously untreated advanced non-small-cell lung cancer. Oncology 2003; 65:224.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/8\" class=\"nounderline abstract_t\">Ayoub JP, North L, Greer J, et al. Pulmonary changes in patients with lymphoma who receive paclitaxel. J Clin Oncol 1997; 15:2476.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/9\" class=\"nounderline abstract_t\">Thomas AL, Cox G, Sharma RA, et al. Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study. Eur J Cancer 2000; 36:2329.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/10\" class=\"nounderline abstract_t\">Read WL, Mortimer JE, Picus J. Severe interstitial pneumonitis associated with docetaxel administration. Cancer 2002; 94:847.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/11\" class=\"nounderline abstract_t\">Ochoa R, Bejarano PA, Gl&uuml;ck S, Montero AJ. Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review. J Med Case Rep 2012; 6:413.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/12\" class=\"nounderline abstract_t\">Tamiya A, Naito T, Miura S, et al. Interstitial lung disease associated with docetaxel in patients with advanced non-small cell lung cancer. Anticancer Res 2012; 32:1103.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/13\" class=\"nounderline abstract_t\">Peddi PF, Cho M, Wang J, et al. Nab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma. J Gastrointest Oncol 2013; 4:370.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/14\" class=\"nounderline abstract_t\">Dimopoulou I, Bamias A, Lyberopoulos P, Dimopoulos MA. Pulmonary toxicity from novel antineoplastic agents. Ann Oncol 2006; 17:372.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/15\" class=\"nounderline abstract_t\">Harries M, Moss C, Perren T, et al. A phase II feasibility study of carboplatin followed by sequential weekly paclitaxel and gemcitabine as first-line treatment for ovarian cancer. Br J Cancer 2004; 91:627.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/16\" class=\"nounderline abstract_t\">Graziano SL, Herndon JE 2nd, Socinski MA, et al. Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901. J Thorac Oncol 2008; 3:158.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/17\" class=\"nounderline abstract_t\">Yasuda K, Igishi T, Kawasaki Y, et al. Phase II study of weekly paclitaxel in patients with non-small cell lung cancer who have failed previous treatments. Oncology 2004; 66:347.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/18\" class=\"nounderline abstract_t\">Maruyama R, Nishiwaki Y, Tamura T, et al. Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer. J Clin Oncol 2008; 26:4244.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/19\" class=\"nounderline abstract_t\">Seidman AD, Berry D, Cirrincione C, et al. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008; 26:1642.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/20\" class=\"nounderline abstract_t\">Chen YM, Shih JF, Perng RP, et al. A randomized trial of different docetaxel schedules in non-small cell lung cancer patients who failed previous platinum-based chemotherapy. Chest 2006; 129:1031.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/21\" class=\"nounderline abstract_t\">Harvey V, Mouridsen H, Semiglazov V, et al. Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer. J Clin Oncol 2006; 24:4963.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/22\" class=\"nounderline abstract_t\">Storaas E, Holmaas G, Gravdal K, et al. Lethal pneumonitis after docetaxel chemotherapy: case report and review of the literature. Acta Oncol 2013; 52:1034.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/23\" class=\"nounderline abstract_t\">Winer EP, Berry DA, Woolf S, et al. Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol 2004; 22:2061.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/24\" class=\"nounderline abstract_t\">Bolis G, Scarfone G, Polverino G, et al. Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: a randomized trial. J Clin Oncol 2004; 22:686.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/25\" class=\"nounderline abstract_t\">Stemmer SM, Cagnoni PJ, Shpall EJ, et al. High-dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor-cell support: a phase I trial. J Clin Oncol 1996; 14:1463.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/26\" class=\"nounderline abstract_t\">McNeish IA, Kanfer EJ, Haynes R, et al. Paclitaxel-containing high-dose chemotherapy for relapsed or refractory testicular germ cell tumours. Br J Cancer 2004; 90:1169.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/27\" class=\"nounderline abstract_t\">Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol 2012; 30:2055.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/28\" class=\"nounderline abstract_t\">Kanaji N, Tadokoro A, Kita N, et al. Impact of idiopathic pulmonary fibrosis on advanced non-small cell lung cancer survival. J Cancer Res Clin Oncol 2016; 142:1855.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/29\" class=\"nounderline abstract_t\">Watanabe N, Niho S, Kirita K, et al. Second-line docetaxel for patients with platinum-refractory advanced non-small cell lung cancer and interstitial pneumonia. Cancer Chemother Pharmacol 2015; 76:69.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/30\" class=\"nounderline abstract_t\">Azuma Y, Tamiya M, Shiroyama T, et al. Nanoparticle Albumin-bound Paclitaxel+Carboplatin Therapy for Small Cell Lung Cancer Combined with Squamous Cell Carcinoma and Interstitial Lung Disease. Intern Med 2015; 54:2911.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/31\" class=\"nounderline abstract_t\">Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 2008; 109:329.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/32\" class=\"nounderline abstract_t\">Katakami N, Takiguchi Y, Yoshimori K, et al. Docetaxel in combination with either cisplatin or gemcitabine in unresectable non-small cell lung carcinoma: a randomized phase II study by the Japan Lung Cancer Cooperative Clinical Study Group. J Thorac Oncol 2006; 1:447.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/33\" class=\"nounderline abstract_t\">Dunsford ML, Mead GM, Bateman AC, et al. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma. Ann Oncol 1999; 10:943.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/34\" class=\"nounderline abstract_t\">Li J, Juliar B, Yiannoutsos C, et al. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study. J Clin Oncol 2005; 23:1185.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/35\" class=\"nounderline abstract_t\">Takeda K, Negoro S, Tamura T, et al. Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104). Ann Oncol 2009; 20:835.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/36\" class=\"nounderline abstract_t\">Briasoulis E, Froudarakis M, Milionis HJ, et al. Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support. Respiration 2000; 67:680.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/37\" class=\"nounderline abstract_t\">Yu TK, Whitman GJ, Thames HD, et al. Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients. J Natl Cancer Inst 2004; 96:1676.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/38\" class=\"nounderline abstract_t\">Kalmadi S, McNeill G, Davis M, et al. Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer. Med Oncol 2006; 23:507.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/39\" class=\"nounderline abstract_t\">Binder D, H&uuml;bner RH, Temmesfeld-Wollbr&uuml;ck B, Schlattmann P. Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials. Cancer Chemother Pharmacol 2011; 68:1575.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/40\" class=\"nounderline abstract_t\">Akerley W, Safran H, Zaner K, et al. Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer. Cancer 2006; 107:1050.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/41\" class=\"nounderline abstract_t\">Nakamura M, Koizumi T, Hayasaka M, et al. Cisplatin and weekly docetaxel with concurrent thoracic radiotherapy for locally advanced stage III non-small-cell lung cancer. Cancer Chemother Pharmacol 2009; 63:1091.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/42\" class=\"nounderline abstract_t\">Onishi H, Kuriyama K, Yamaguchi M, et al. Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis. Lung Cancer 2003; 40:79.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/43\" class=\"nounderline abstract_t\">Hanna YM, Baglan KL, Stromberg JS, et al. Acute and subacute toxicity associated with concurrent adjuvant radiation therapy and paclitaxel in primary breast cancer therapy. Breast J 2002; 8:149.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/44\" class=\"nounderline abstract_t\">Hasegawa T, Futamura Y, Horiba A, et al. A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer. J Radiat Res 2016; 57:50.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/45\" class=\"nounderline abstract_t\">Sekine I, Nokihara H, Sumi M, et al. Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer. J Thorac Oncol 2006; 1:810.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/46\" class=\"nounderline abstract_t\">Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008; 26:5755.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/47\" class=\"nounderline abstract_t\">Taghian AG, Assaad SI, Niemierko A, et al. Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst 2001; 93:1806.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/48\" class=\"nounderline abstract_t\">Beal K, Hudis C, Norton L, et al. Radiation pneumonitis in breast cancer patients treated with taxanes: does sequential radiation therapy lower the risk? Breast J 2005; 11:317.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/49\" class=\"nounderline abstract_t\">Gandara DR, Chansky K, Albain KS, et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003; 21:2004.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/50\" class=\"nounderline abstract_t\">Wang S, Liao Z, Wei X, et al. Association between systemic chemotherapy before chemoradiation and increased risk of treatment-related pneumonitis in esophageal cancer patients treated with definitive chemoradiotherapy. J Thorac Oncol 2008; 3:277.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/51\" class=\"nounderline abstract_t\">Kishida Y, Tsushima T, Endo M, et al. Risk Analysis of Pneumonitis in Taxane Therapy After Chemoradiotherapy for Patients With Metastatic or Recurrent Esophageal Cancer. Am J Clin Oncol 2015.</a></li><li class=\"breakAll\">Camus P. The Drug-Induced Respiratory Disease Website. www.pneumotox.com (Accessed on September 25, 2016).</li><li class=\"breakAll\">Camus P. Interstitial lung disease from drugs, biologics, and radiation. In: Interstitial Lung Disease, 5th, Schwarz MI, King TE, Jr. (Eds), People's Medical Publishing House - USA, Shelton, CT 2011. p.637.</li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/54\" class=\"nounderline abstract_t\">Fujimaki T, Kato K, Fukuda S, et al. Acute interstitial pneumonitis after implantation of paclitaxel-eluting stents: a report of two fatal cases. Int J Cardiol 2011; 148:e21.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/55\" class=\"nounderline abstract_t\">Ramanathan RK, Reddy VV, Holbert JM, Belani CP. Pulmonary infiltrates following administration of paclitaxel. Chest 1996; 110:289.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/56\" class=\"nounderline abstract_t\">Cleverley JR, Screaton NJ, Hiorns MP, et al. Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol 2002; 57:292.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/57\" class=\"nounderline abstract_t\">Wong P, Leung AN, Berry GJ, et al. Paclitaxel-induced hypersensitivity pneumonitis: radiographic and CT findings. AJR Am J Roentgenol 2001; 176:718.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/58\" class=\"nounderline abstract_t\">Genestreti G, Di Battista M, Trisolini R, et al. A commentary on interstitial pneumonitis induced by docetaxel: clinical cases and systematic review of the literature. Tumori 2015; 101:e92.</a></li><li class=\"breakAll\">Camus P, White DA. Drugs and the lungs. In: Clinical Respiratory Medicine, 3rd, Albert RK, Spiro SG, Jett JR (Eds), Mosby Elsevier, Philadelphia 2008.</li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/60\" class=\"nounderline abstract_t\">Hasskarl J, Schroettner P, von den Berg A, et al. Severe Organizing Pneumonia after Two Cycles of Docetaxel as Fourth-Line Chemotherapy for Advanced Non-Small Cell Carcinoma of the Lung. Case Rep Oncol 2009; 2:12.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/61\" class=\"nounderline abstract_t\">Cobo Dols M, Gil Calle S, Al&eacute;s D&iacute;az I, et al. Bronchiolitis obliterans organizing pneumonia simulating progression in bronchioloalveolar carcinoma. Clin Transl Oncol 2006; 8:133.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/62\" class=\"nounderline abstract_t\">Nagata S, Ueda N, Yoshida Y, et al. Severe interstitial pneumonitis associated with the administration of taxanes. J Infect Chemother 2010; 16:340.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/63\" class=\"nounderline abstract_t\">Suzaki N, Hiraki A, Takigawa N, et al. Severe interstitial pneumonia induced by paclitaxel in a patient with adenocarcinoma of the lung. Acta Med Okayama 2006; 60:295.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/64\" class=\"nounderline abstract_t\">Leimgruber K, Negro R, Baier S, et al. Fatal interstitial pneumonitis associated with docetaxel administration in a patient with hormone-refractory prostate cancer. Tumori 2006; 92:542.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/65\" class=\"nounderline abstract_t\">Cortes JE, Pazdur R. Docetaxel. J Clin Oncol 1995; 13:2643.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/66\" class=\"nounderline abstract_t\">Kenmotsu H, Tanigawara Y. Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose. Cancer Sci 2015; 106:497.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/67\" class=\"nounderline abstract_t\">Bruno R, Hille D, Riva A, et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. J Clin Oncol 1998; 16:187.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/68\" class=\"nounderline abstract_t\">Amathieu R, Tual L, Fessenmeyer C, Dhonneur G. [Docetaxel-induced acute pulmonary capillary-leak syndrome mimicking cardiogenic oedema]. Ann Fr Anesth Reanim 2007; 26:180.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/69\" class=\"nounderline abstract_t\">Martin M, Pienkowski T, Mackey J, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005; 352:2302.</a></li><li class=\"breakAll\">Docetaxel injection. United States Prescribing Information. US National Library of Medicine. www.dailymed.nlm.nih.gov (Accessed on September 27, 2016).</li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/71\" class=\"nounderline abstract_t\">Semb KA, Aamdal S, Oian P. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment. J Clin Oncol 1998; 16:3426.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/72\" class=\"nounderline abstract_t\">Kang RY, Yoo KS, Han HJ, et al. Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel. Support Care Cancer 2017; 25:429.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/73\" class=\"nounderline abstract_t\">Hosonaga M, Ito Y, Tokudome N, et al. A lower dose of docetaxel at 60&nbsp;mg/m(2) could be continued longer for controlling peripheral edema in patients with metastatic breast cancer. Breast Cancer 2012; 19:329.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/74\" class=\"nounderline abstract_t\">Schweitzer VG, Juillard GJ, Bajada CL, Parker RG. Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel. Cancer 1995; 76:1069.</a></li><li><a href=\"https://www.uptodate.com/contents/taxane-induced-pulmonary-toxicity/abstract/75\" class=\"nounderline abstract_t\">Malik SM, Collins B, Pishvaian M, et al. A phase I trial of bexarotene in combination with docetaxel in patients with advanced solid tumors. Clin Lung Cancer 2011; 12:231.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 4355 Version 16.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H13\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">INTERSTITIAL PNEUMONITIS</a><ul><li><a href=\"#H1346056356\" id=\"outline-link-H1346056356\">Paclitaxel, docetaxel, and nabpaclitaxel</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">- Incidence and impact of dose and schedule</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">- Concomitant drugs</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">- Concomitant radiotherapy</a></li><li><a href=\"#H2722231576\" id=\"outline-link-H2722231576\">- Patterns of disease</a></li><li><a href=\"#H3973614121\" id=\"outline-link-H3973614121\">- Clinical manifestations</a></li><li><a href=\"#H1549027504\" id=\"outline-link-H1549027504\">- Diagnostic evaluation</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">- Treatment</a></li></ul></li><li><a href=\"#H4158011296\" id=\"outline-link-H4158011296\">Cabazitaxel</a></li></ul></li><li><a href=\"#H11\" id=\"outline-link-H11\">CAPILLARY LEAKAGE AND DOCETAXEL</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">RADIATION RECALL</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">SUMMARY AND RECOMMENDATIONS</a><ul><li><a href=\"#H3200253800\" id=\"outline-link-H3200253800\">Interstitial pneumonitis</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">Docetaxel-related capillary leakage</a></li></ul></li><li><a href=\"#H1393696056\" id=\"outline-link-H1393696056\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ONC/4355|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/51035\" class=\"graphic graphic_diagnosticimage\">- Paclitaxel pneumonitis</a></li></ul></li><li><div id=\"ONC/4355|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/76456\" class=\"graphic graphic_table\">- Chemotherapy infusion reaction types</a></li><li><a href=\"image.htm?imageKey=ALLRG/72225\" class=\"graphic graphic_table\">- Diagnostic criteria for anaphylaxis</a></li><li><a href=\"image.htm?imageKey=PULM/71375\" class=\"graphic graphic_table\">- Types of allergic reactions</a></li><li><a href=\"image.htm?imageKey=ONC/61493\" class=\"graphic graphic_table\">- NCI CTCAE v5 pneumonitis</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=acute-interstitial-pneumonia-hamman-rich-syndrome\" class=\"medical medical_review\">Acute interstitial pneumonia (Hamman-Rich syndrome)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-adult-with-interstitial-lung-disease-clinical-evaluation\" class=\"medical medical_review\">Approach to the adult with interstitial lung disease: Clinical evaluation</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=approach-to-the-adult-with-interstitial-lung-disease-diagnostic-testing\" class=\"medical medical_review\">Approach to the adult with interstitial lung disease: Diagnostic testing</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=drug-eluting-intracoronary-stents-general-principles\" class=\"medical medical_review\">Drug-eluting intracoronary stents: General principles</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=high-resolution-computed-tomography-of-the-lungs\" class=\"medical medical_review\">High resolution computed tomography of the lungs</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=idiopathic-interstitial-pneumonias-clinical-manifestations-and-pathology\" class=\"medical medical_review\">Idiopathic interstitial pneumonias: Clinical manifestations and pathology</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infusion-reactions-to-systemic-chemotherapy\" class=\"medical medical_review\">Infusion reactions to systemic chemotherapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pulmonary-toxicity-associated-with-systemic-antineoplastic-therapy-clinical-presentation-diagnosis-and-treatment\" class=\"medical medical_review\">Pulmonary toxicity associated with systemic antineoplastic therapy: Clinical presentation, diagnosis, and treatment</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=radiation-induced-lung-injury\" class=\"medical medical_review\">Radiation-induced lung injury</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=role-of-bronchoalveolar-lavage-in-diagnosis-of-interstitial-lung-disease\" class=\"medical medical_review\">Role of bronchoalveolar lavage in diagnosis of interstitial lung disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=role-of-lung-biopsy-in-the-diagnosis-of-interstitial-lung-disease\" class=\"medical medical_review\">Role of lung biopsy in the diagnosis of interstitial lung disease</a></li></ul></div></div>","javascript":null}